NasdaqGS:ACAD

Stock Analysis Report

Executive Summary

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Share Price & News

How has ACADIA Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.7%

NasdaqGS:ACAD

1.7%

US Biotechs

2.1%

US Market


1 Year Return

104.8%

NasdaqGS:ACAD

-9.1%

US Biotechs

-0.04%

US Market

ACAD outperformed the Biotechs industry which returned -8.8% over the past year.

ACAD outperformed the Market in United States of America which returned 0.2% over the past year.


Share holder returns

ACADIndustryMarket
7 Day0.7%1.7%2.1%
30 Day31.5%0.7%-3.2%
90 Day12.5%2.4%2.8%
1 Year104.8%104.8%-8.3%-9.1%2.2%-0.04%
3 Year-9.6%-9.6%11.9%8.1%41.5%32.3%
5 Year23.7%23.7%5.2%0.3%55.0%37.8%

Price Volatility Vs. Market

How volatile is ACADIA Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ACADIA Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

34%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

ACADIA Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

ACADIA Pharmaceuticals's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

ACADIA Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

ACADIA Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ACADIA Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

ACADIA Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is ACADIA Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

70.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ACADIA Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

ACADIA Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

ACADIA Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

ACADIA Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

ACADIA Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if ACADIA Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has ACADIA Pharmaceuticals performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ACADIA Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare ACADIA Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ACADIA Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ACADIA Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ACADIA Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ACADIA Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ACADIA Pharmaceuticals's financial position?


Financial Position Analysis

ACADIA Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ACADIA Pharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ACADIA Pharmaceuticals has no debt.

ACADIA Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

ACADIA Pharmaceuticals has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ACADIA Pharmaceuticals has sufficient cash runway for 2 years based on current free cash flow.

ACADIA Pharmaceuticals has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -6.5% each year.


Next Steps

Dividend

What is ACADIA Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ACADIA Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ACADIA Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ACADIA Pharmaceuticals has not reported any payouts.

Unable to verify if ACADIA Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ACADIA Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of ACADIA Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of ACADIA Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Steve Davis (58yo)

3.9yrs

Tenure

US$6,508,032

Compensation

Mr. Stephen R. Davis, also known as Steve, J.D., has been the Chief Executive Officer of ACADIA Pharmaceuticals, Inc. since September 1, 2015 and served as its Chief Financial Officer from July 15, 2014 to ...


CEO Compensation Analysis

Steve's remuneration is about average for companies of similar size in United States of America.

Steve's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.0yrs

Average Tenure

57yo

Average Age

The average tenure for the ACADIA Pharmaceuticals management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.8yrs

Average Tenure

62yo

Average Age

The tenure for the ACADIA Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$199,999,98504 Dec 18
Baker Bros. Advisors LP
EntityCompany
Shares11,764,705
Max PriceUS$17.00
BuyUS$22,646,98924 Sep 18
Baker Bros. Advisors LP
EntityCompany
Shares1,210,776
Max PriceUS$19.09

Ownership Breakdown


Management Team

  • Steve Davis (58yo)

    CEO & Director

    • Tenure: 3.9yrs
    • Compensation: US$6.51m
  • Eliseo Salinas (63yo)

    Senior VP

    • Tenure: 0.9yrs
  • Elena Ridloff (39yo)

    Executive VP & CFO

    • Tenure: 0.8yrs
  • Serge Stankovic (62yo)

    President

    • Tenure: 0.8yrs
    • Compensation: US$5.68m
  • Ryan Brown

    Chief Compliance Officer & VP

    • Tenure: 4.0yrs
  • Bob Mischler

    Senior Vice President of Strategy & Technology Operations

    • Tenure: 0.0yrs
  • Mark Johnson

    Vice President of Investor Relations

    • Tenure: 0.0yrs
  • Michael Yang (57yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 2.4yrs
    • Compensation: US$3.18m
  • Austin Kim (55yo)

    Executive VP

    • Tenure: 1.1yrs
    • Compensation: US$2.13m
  • Eric Miller (40yo)

    Controller & Principal Accounting Officer

    • Tenure: 0.8yrs

Board Members

  • Laura Brege (61yo)

    Independent Director

    • Tenure: 11.3yrs
    • Compensation: US$793.63k
  • Steve Davis (58yo)

    CEO & Director

    • Tenure: 3.9yrs
    • Compensation: US$6.51m
  • Jim Baker (52yo)

    Independent Director

    • Tenure: 3.7yrs
    • Compensation: US$231.28k
  • Paul Anderson (80yo)

    Member of the Scientific and Clinical Advisory Board

    • Tenure: 0.0yrs
  • Ed Harrigan (66yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$394.55k
  • Dan Soland (63yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$412.57k
  • Arvid Carlsson (96yo)

    Member of the Scientific and Clinical Advisory Board

    • Tenure: 0.0yrs
  • Carol Tamminga

    Member of the Scientific and Clinical Advisory Board

    • Tenure: 0.0yrs
  • Herb Meltzer

    Member of the Scientific and Clinical Advisory Board

    • Tenure: 0.0yrs
  • Stephen Biggar (48yo)

    Chairman of the Board

    • Tenure: 3.2yrs
    • Compensation: US$276.28k

Company Information

ACADIA Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ACADIA Pharmaceuticals Inc.
  • Ticker: ACAD
  • Exchange: NasdaqGS
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.220b
  • Shares outstanding: 144.49m
  • Website: https://www.acadia-pharm.com

Number of Employees


Location

  • ACADIA Pharmaceuticals Inc.
  • 3611 Valley Centre Drive
  • Suite 300
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ACADNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2004
DR6DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2004

Biography

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/22 23:52
End of Day Share Price2019/08/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.